Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2014 Jan;29(1):23-6.
doi: 10.3904/kjim.2014.29.1.23. Epub 2014 Jan 2.

Risks associated with sunitinib use and monitoring to improve patient outcomes

Bum Soon Choi  1
Affiliations
Editorial

Risks associated with sunitinib use and monitoring to improve patient outcomes

Bum Soon Choi. Korean J Intern Med. 2014 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article is reported.

Comment on

References

    1. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358:2039–2049. - PMC - PubMed
    1. Zhou A. Management of sunitinib adverse events in renal cell carcinoma patients: the Asian experience. Asia Pac J Clin Oncol. 2012;8:132–144. - PubMed
    1. Sivendran S, Liu Z, Portas LJ, Jr, et al. Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis. Cancer Treat Rev. 2012;38:919–925. - PubMed
    1. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329–1338. - PubMed
    1. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124. - PubMed

LinkOut - more resources